Annovis Bio, Inc. (ANVS)
- Previous Close
11.49 - Open
11.57 - Bid 11.19 x 1200
- Ask --
- Day's Range
11.40 - 12.34 - 52 Week Range
5.42 - 22.49 - Volume
226,191 - Avg. Volume
225,508 - Market Cap (intraday)
130.814M - Beta (5Y Monthly) 1.59
- PE Ratio (TTM)
-- - EPS (TTM)
-6.23 - Earnings Date May 9, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
35.40
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. Annovis Bio, Inc. was incorporated in 2008 and is based in Malvern, Pennsylvania.
www.annovisbio.comRecent News: ANVS
Performance Overview: ANVS
Trailing total returns as of 4/23/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ANVS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ANVS
Valuation Measures
Market Cap
130.81M
Enterprise Value
125.06M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
19.68
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-2.78
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-121.77%
Return on Equity (ttm)
-546.40%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-56.2M
Diluted EPS (ttm)
-6.23
Balance Sheet and Cash Flow
Total Cash (mrq)
5.75M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-23.75M